Advertisement
UK markets close in 3 hours 46 minutes

  • FTSE 100

    8,155.35
    +34.11 (+0.42%)
     

  • FTSE 250

    19,964.06
    +37.47 (+0.19%)
     

  • AIM

    766.23
    +1.25 (+0.16%)
     

  • GBP/EUR

    1.1689
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2512
    -0.0012 (-0.10%)
     

  • Bitcoin GBP

    46,620.43
    +665.66 (+1.45%)
     

  • CMC Crypto 200

    1,261.89
    -8.85 (-0.70%)
     

  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     

  • DOW

    37,903.29
    +87.37 (+0.23%)
     

  • CRUDE OIL

    79.52
    +0.52 (+0.66%)
     

  • GOLD FUTURES

    2,308.70
    -2.30 (-0.10%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • HANG SENG

    18,207.13
    +444.10 (+2.50%)
     

  • DAX

    17,951.51
    +19.34 (+0.11%)
     

  • CAC 40

    7,935.93
    -49.00 (-0.61%)
     
Money:

Best UK mortgage deals of the week

The cheapest home loans available now

Allergan rebuffed in seeking offers to combat Valeant bid-report

Reuters - UK Focus

(Refiled to remove extraneous text characters in headline)

May 11 (Reuters) - U.S. medical firm Allergan Inc (NYSE: AGN - news) declined to comment on Sunday on a report that it has been seeking offers from rival companies to combat Valeant Pharmaceuticals International's $47 billion cash and share offer.

A spokeswoman for Allergan told Reuters on Sunday the company had no comment to make on whether it was seeking offers from other companies, following a report by Bloomberg that Allergan has so far been rebuffed by rival companies it has tried to interest in making an offer.

Allergan contacted both Sanofi SA and Johnson & Johnson after Valeant made its offer on April 22, Bloomberg said, as well as GlaxoSmithKline Plc (Other OTC: GLAXF - news) and Novartis AG (Xetra: NOT.DE - news) . (Reporting by Scott DiSavino; Editing by Greg Mahlich)